Last reviewed · How we verify
Pfizer Inc. — Portfolio Competitive Intelligence Brief
PFE (NYSE)
689 marketed
0 filed
124 Phase 3
217 Phase 2
438 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Pf-08052666 | pf-08052666 | marketed | Small molecule inhibitor | Specific protein involved in disease pathways | Other | Unknown |
| Pf-08046045 | pf-08046045 | marketed | Small molecule inhibitor | Specific protein involved in cancer cell proliferation | Oncology | TBD |
| mPnC candidate | mpnc-candidate | marketed | Novel therapeutic agent | Specific protein or receptor involved in disease pathology | Immunology | TBD |
| PF-07321332 Dose 5 | pf-07321332-dose-5 | marketed | Protease inhibitor | Main protease (MPro) of SARS-CoV-2 | Pending regulatory approval | |
| Isauvuconazole group | isauvuconazole-group | marketed | Echinocandin | β-(1,3)-D-glucan synthase | Other | Not yet launched |
| Talazoparib with enzalutamide | talazoparib-with-enzalutamide | marketed | PARP inhibitor and androgen receptor inhibitor | PARP enzymes and androgen receptor | Oncology | Not yet launched |
| Test formulation (Treatment A) | test-formulation-treatment-a | marketed | Enzyme inhibitor | Specific enzyme | Infectious Disease | Not yet determined |
| PF-06939999 in combination with docetaxel | pf-06939999-in-combination-with-docetaxel | marketed | Small molecule inhibitor | Specific protein kinase | Oncology | Not yet determined |
| [89Zr]Zr-crefmirlimab berdoxam | 89zr-zr-crefmirlimab-berdoxam | marketed | Radiolabeled Monoclonal Antibody | Fibroblast Activation Protein (FAP) | Oncology | Not specified |
| Pf-07220060 | pf-07220060 | marketed | Small molecule inhibitor | Specific protein involved in disease pathways | Oncology | Not available |
| Pf-07293893 | pf-07293893 | marketed | JAK inhibitor | Janus kinase (JAK) pathway | Oncology | Not available |
| Pf-07248144 | pf-07248144 | marketed | Small molecule inhibitor | Specific protein involved in disease pathways | Oncology | Not available |
Therapeutic area mix
- Oncology · 230
- Immunology · 116
- Other · 103
- Infectious Disease · 95
- Metabolic · 55
- Neuroscience · 52
- Cardiovascular · 38
- Dermatology · 18
- Rare Disease · 12
- Hematology · 11
Recent regulatory actions (last 90 days)
- — Merrem · FDA · approved · US
- — Glucotrol · FDA · approved · US
- — Lyrica · FDA · approved · US
- — Elrexfio · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Naloxone Hydrochloride · 7731686 · Formulation · US
- — Pantoprazole Sodium · 7544370 · US
- — Arthrotec · 8927604 · US
- — Arthrotec · 8097651 · US
- — Arthrotec · 9827197 · US
- — Arthrotec · 7759394 · US
- — Naloxone Hydrochloride · 10960155 · Formulation · US
- — Torisel · 8026276*PED · US
- — Taxol · 8034375 · Method of Use · US
- — Taxol · 8034375 · US
- — Taxol · 8034375 · US
- — Taxol · 7758891*PED · Compound · US
- — Taxol · 7758891*PED · US
- — Taxol · 8268348*PED · US
- — Taxol · 8268348*PED · Compound · US
- — Taxol · 7758891*PED · US
- — Taxol · 9101543*PED · US
- — Taxol · 9101543*PED · US
- — Taxol · 9101543*PED · Compound · US
- — Taxol · 8268348*PED · US
- — Lyrica · 9144559 · Formulation · US
- — Lyrica · 10022447 · Method of Use · US
- — Lyrica · 8945620 · Formulation · US
- — Cleocin T · 9789057 · Formulation · US
- — Pantoprazole Sodium · 7544370*PED · US
- — Epipen · 11590286 · Formulation · US
- — Bupivacaine Hydrochloride And Epinephrine · 11590286 · Formulation · US
- — Naloxone Hydrochloride · 11590286 · Formulation · US
- — Camptosar · 8329213 · US
- — Camptosar · 8329213 · Compound · US
Competitive overlap (companies sharing drug classes)
- · 59 shared drug classes
- GlaxoSmithKline · 29 shared drug classes
- Merck Sharp & Dohme LLC · 28 shared drug classes
- Sanofi · 26 shared drug classes
- Novartis · 20 shared drug classes
- AstraZeneca · 19 shared drug classes
- Assistance Publique - Hôpitaux de Paris · 16 shared drug classes
- Bayer · 14 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Pfizer Inc.:
- Pfizer Inc. pipeline updates — RSS
- Pfizer Inc. pipeline updates — Atom
- Pfizer Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Pfizer Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pfizer. Accessed 2026-05-13.